Parallel Trade 2017
6 – 7 February 2017, London, UK
With Brexit and the new EU Falsified Medicine Directive, what does the future hold for parallel trade? Parallel Trade 2017 will discuss short term and long term concerns of pharma manufacturers, regulators and parallel traders.
They will engage in an interactive debate and discuss how to keep abreast of the current trends and how to overcome all challenges.
Key topics to be discussed during the 2-day conference are: The European Commission’s Falsified Medicines Directive – recent updates; What will Brexit mean for parallel trade to and from the UK; Parallel Trade 101 - Which factors determine the flow of pharmaceutical products in Europe; Beyond pharmaceutical products – parallel imports of medical devices; The Patient’s perspective and so much more.
The event programme also features three panel debates on: Shortages; Challenges and opportunities for parallel traders; Technology & new trends; and two exclusive post conference workshops on “Understanding IP and competition law issues in parallel trade” (Hosted by Kathy Osgerby, Associate and Karoline Zwierzynska, Associate, Arnold & Porter (UK) LLP) and “Parallel Trade – Management Strategies” (Hosted by Janice Haigh, Practice Leader, Market Access, Quintiles).
Expert Speakers Line up for 2017 includes: The Association of the British Pharmaceutical Industry (Dr Rick Greville, Director Distribution & Supply), Shire International GmbH (Eric Noehrenberg, Director, Regional Market Access Lead, Latin America), Delfarma (Tomasz Dzitko, President), European Association for Euro-Pharmaceutical Companies (Heinz Kobelt, Director European Affairs), ISPOR (Vladimir Zah, Health Economics Consultant), Abacus Medicine (Flemming Wagner, CEO), IMS Health (Alexey Savin, Principal Russia and CIS), Arnold & Porter (UK) LLP (Kathy Osgerby, Associate, and Karoline Zwierzynska, Associate), Europe Economics (Dermot Glynn, Senior Advisor), European Alliance for Access to Save Medicines (Mike Isles, Executive Director), Research Health (Dr Andrew Stainthorpe, Director Market Access and Managed Entry) and many more.
Feedback from past attendees of SMi Group’s Parallel Trade: “Interesting conference, generating a good debate from all sides”, “Great conference! Audience very enthusiastic and actively participating in discussions”, “Very good discussing about pricing issues and competition”, “Overall, a very positive experience!”, “The best Parallel Trade conference of the last 5 years!”.
More details at; www.parallel-trade.com/farmavita